AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19001601 — intervention group
Group type: EXPERIMENTAL
Intervention: 25‐hydroxyvitamin D levels
Number of subjects: 36282
Study 16095421 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy resistance training (HRT, 80% of 1 repetition maximum [1RM])
Number of subjects: 33
Study 16095421 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate resistance training (MRT, 60% of 1 repetition maximum [1RM])
Number of subjects: 33
Study 16095421 — intervention group
Group type: COMPARATOR
Intervention: Control group (CS)
Number of subjects: 33
Study 11923060 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalat OROS
Number of subjects: 24
Study 11923060 — intervention group
Group type: EXPERIMENTAL
Intervention: CORAL
Number of subjects: 24
Study 11923060 — intervention group
Group type: EXPERIMENTAL
Intervention: CORAL under fed conditions
Number of subjects: 24
Study 11923060 — intervention group
Group type: COMPARATOR
Intervention: CORAL vs Adalat OROS under fed conditions
Number of subjects: 24
Study 9893199 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentil ingestion
Number of subjects: 22
Study 9893199 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to steam from cooked lentils
Number of subjects: 22
Study 9893199 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergic reactions to other legumes (chick peas, peas, green beans)
Number of subjects: 22
Study 9893199 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific IgE antibodies to lentil extract
Number of subjects: 22
Study 7557504 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa/Carbidopa administered daily for 3 weeks
Number of subjects: 0
Study 7557504 — intervention group
Group type: COMPARATOR
Intervention: Levodopa/Carbidopa (1 week administration)
Number of subjects: 0
Study 2150181 — intervention group
Group type: EXPERIMENTAL
Intervention: Prismashield
Number of subjects: 133
Study 2150181 — intervention group
Group type: COMPARATOR
Intervention: Estiseal
Number of subjects: 133
Study 2150181 — intervention group
Group type: COMPARATOR
Intervention: Concise
Number of subjects: 133
Study 7225648 — intervention group
Group type: EXPERIMENTAL
Intervention: mexiletine
Number of subjects: 21
Study 7225648 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam
Number of subjects: 21
Study 7225648 — intervention group
Group type: EXPERIMENTAL
Intervention: betahistine
Number of subjects: 21
Study 7225648 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 21
Study 30646170 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive psychological intervention (6-week series of evidence-based activities to build positive psychological skills)
Number of subjects: 360
Study 30646170 — intervention group
Group type: COMPARATOR
Intervention: Neutral control intervention (similarly structured neutral activities)
Number of subjects: 360
Study 26036956 — intervention group
Group type: EXPERIMENTAL
Intervention: Water extracts of Graptopetalum paraguayense (WGP, 4 g day(-1))
Number of subjects: 42
Study 26036956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 24434439 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive atorvastatin therapy (80 mg/day)
Number of subjects: 66
Study 24434439 — intervention group
Group type: COMPARATOR
Intervention: Conventional atorvastatin therapy (20 mg/day)
Number of subjects: 66
Study 23128898 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 Gy single dose
Number of subjects: 312
Study 23128898 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 Gy single dose
Number of subjects: 312
Study 19460871 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg of oral lorazepam
Number of subjects: 18
Study 19460871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 18611212 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about sun safety
Number of subjects: 1782
Study 18611212 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer norms
Number of subjects: 1782
Study 18611212 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer norms (among ethnic groups)
Number of subjects: 1782
Study 18611212 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers regarding sun exposure
Number of subjects: 1782
Study 15885165 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuhuang Tablets (4 tablets t.i.d. per os)
Number of subjects: 144
Study 15885165 — intervention group
Group type: COMPARATOR
Intervention: Zhining Tablets (4 tablets t.i.d. per os)
Number of subjects: 144
Study 12204869 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant vitamin supplementation (50 mg/day of vitamin E and 250 mg/day of vitamin C)
Number of subjects: 158
Study 12204869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 10579255 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidified enteral feeds (pH = 3.5)
Number of subjects: 120
Study 10579255 — intervention group
Group type: COMPARATOR
Intervention: Standard feeding formula (Vital High Nitrogen, pH = 6.5)
Number of subjects: 120
Study 10579255 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidified enteral feeds
Number of subjects: 120
Study 10579255 — intervention group
Group type: COMPARATOR
Intervention: Standard feeding formula
Number of subjects: 120
Study 8796633 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral thrombolysis RCTs
Number of subjects: 9
Study 2064061 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.175% bupivacaine
Number of subjects: 122
Study 2064061 — intervention group
Group type: COMPARATOR
Intervention: 0.15% bupivacaine
Number of subjects: 122
Study 2064061 — intervention group
Group type: EXPERIMENTAL
Intervention: greater than or equal to 0.2% bupivacaine
Number of subjects: 122
Study 2064061 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine
Number of subjects: 122
Study 6364333 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole (4 X 500 mg in one single dose)
Number of subjects: 26
Study 6364333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 6364333 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole (4 X 500 mg in one single dose) for non-responders
Number of subjects: 26
Study 6364333 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (250 mg, 4 times daily, for one week)
Number of subjects: 26
Study 30769227 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (2 years)
Number of subjects: 564
Study 30769227 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 564
Study 29226773 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-based intervention (48 weeks)
Number of subjects: 64
Study 29226773 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 64
Study 27112810 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (CT) with computerized cognitive rehabilitation and right hemifield eye-patching, 15 one-hour sessions
Number of subjects: 28
Study 27112810 — intervention group
Group type: COMPARATOR
Intervention: Single treatment (ST) with computerized cognitive rehabilitation, 15 one-hour sessions
Number of subjects: 28
Study 26009783 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy consisting of exposure and ritual prevention (EX/RP)
Number of subjects: 100
Study 26009783 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 100
Study 26009783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 22228392 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Management Program (PMP)
Number of subjects: 38
Study 22228392 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 38
Study 20080960 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional composite (Transbond‐XT; 3M Unitek)
Number of subjects: 40
Study 20080960 — intervention group
Group type: COMPARATOR
Intervention: ACP‐containing orthodontic composite (Aegis‐Ortho; Harry J. Bosworth Co.)
Number of subjects: 40
Study 18825438 — intervention group
Group type: EXPERIMENTAL
Intervention: 375 microg interferon beta-1b (sc every other day)
Number of subjects: 76
Study 18825438 — intervention group
Group type: COMPARATOR
Intervention: 250 microg interferon beta-1b (sc every other day)
Number of subjects: 76
Study 15839922 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin 10 mg
Number of subjects: 625
Study 15839922 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin 15 mg
Number of subjects: 625
Study 15839922 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg
Number of subjects: 625
Study 15839922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 625
Study 11975032 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional cholecystectomy (TCE)
Number of subjects: 278
Study 11975032 — intervention group
Group type: COMPARATOR
Intervention: Minimally invasive cholecystectomy
Number of subjects: 278
Study 11975032 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy
Number of subjects: 278
Study 10333052 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (group 1, n = 7)
Number of subjects: 13
Study 10333052 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (group 2, n = 6)
Number of subjects: 13
Study 10333052 — intervention group
Group type: COMPARATOR
Intervention: Reference group without antihypertensive treatment (group 3, n = 9)
Number of subjects: 13
Study 8600966 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol (Visipaque)
Number of subjects: 120
Study 8600966 — intervention group
Group type: COMPARATOR
Intervention: Ioxaglate (Hexabrix)
Number of subjects: 120
Study 8600966 — intervention group
Group type: EXPERIMENTAL
Intervention: Both contrast media
Number of subjects: 120
Study 6403772 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 0
Study 6403772 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunostomy feedings
Number of subjects: 0
Study 6403772 — intervention group
Group type: COMPARATOR
Intervention: Eating ad libitum
Number of subjects: 0
Study 6403772 — intervention group
Group type: COMPARATOR
Intervention: TPN
Number of subjects: 0
Study 30829116 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Navigator (PN) program
Number of subjects: 102
Study 30829116 — intervention group
Group type: COMPARATOR
Intervention: Decliners of the HPV vaccine
Number of subjects: 102
Study 28187915 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2330672
Number of subjects: 22
Study 26980340 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg once daily celecoxib
Number of subjects: 330
Study 26980340 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg once daily celecoxib
Number of subjects: 330
Study 26980340 — intervention group
Group type: COMPARATOR
Intervention: 50 mg three times daily diclofenac
Number of subjects: 330
Study 25053766 — intervention group
Group type: EXPERIMENTAL
Intervention: Music Therapy Group (MTG)
Number of subjects: 17
Study 25053766 — intervention group
Group type: COMPARATOR
Intervention: No-Music Social Skills Group (SSG)
Number of subjects: 17
Study 22573676 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on spectral modulation (0.5 cyc/oct; 0 Hz)
Number of subjects: 0
Study 22573676 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on temporal modulation (0 cyc/oct; 32 Hz)
Number of subjects: 0
Study 22573676 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on upward spectrotemporal modulation (0.5 cyc/oct; 32 Hz)
Number of subjects: 0
Study 22573676 — intervention group
Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 0
Study 22573676 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on discrimination tasks
Number of subjects: 0
Study 18270762 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with intravenous injection of 5 mg/kg of hematoporphyrin monomethyl ether followed by endoscopic irradiation for 40 min at 150 mW/cm².
Number of subjects: 14
Study 18270762 — intervention group
Group type: COMPARATOR
Intervention: Control group (no photodynamic therapy).
Number of subjects: 14
Study 17234503 — intervention group
Group type: EXPERIMENTAL
Intervention: HFCS-sweetened beverages
Number of subjects: 30
Study 17234503 — intervention group
Group type: COMPARATOR
Intervention: Sucrose-sweetened beverages
Number of subjects: 30
Study 17328728 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone plus Azithromycin
Number of subjects: 278
Study 17328728 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone plus Clarithromycin or Erythromycin
Number of subjects: 278
Study 15017018 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intravenous (IV) and intra-arterial (IA) rt-PA treatment (0.6 mg/kg IV rt-PA, maximum 60 mg over 30 minutes, plus additional rt-PA via microcatheter up to 22 mg over 2 hours)
Number of subjects: 80
Study 15017018 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intravenous (IV) and intra-arterial (IA) rt-PA treatment
Number of subjects: 80
Study 15017018 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 80
Study 15017018 — intervention group
Group type: COMPARATOR
Intervention: rt-PA treatment
Number of subjects: 80
Study 10792277 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous chlorambucil (0.1 mg/kg/d for 7 days, repeated every 6 weeks)
Number of subjects: 46
Study 10792277 — intervention group
Group type: COMPARATOR
Intervention: Intermittent chlorambucil (0.3 mg/kg/d for 7 days, repeated every 6 weeks)
Number of subjects: 46
Study 10792277 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous chlorambucil
Number of subjects: 46
Study 10792277 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 46
Study 8095058 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG IL‐2 at 5 x 10(6) IU/m2
Number of subjects: 19
Study 8095058 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG IL‐2 at 3 x 10(6) IU/m2
Number of subjects: 19
Study 8095058 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG IL‐2
Number of subjects: 19
Study 8095058 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG IL‐2 at 10(6) IU/m2 for 8 weeks
Number of subjects: 19
Study 8095058 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG IL‐2 at 3 x 10(6) IU/m2 for up to 16 weeks
Number of subjects: 19
Study 3530649 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg orally)
Number of subjects: 15
Study 3530649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31545636 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychopathic traits
Number of subjects: 661
Study 31545636 — intervention group
Group type: COMPARATOR
Intervention: Nonviolent or violent psychopath descriptions
Number of subjects: 661
Study 31545636 — intervention group
Group type: COMPARATOR
Intervention: Nonviolent or violent person with schizophrenia descriptions
Number of subjects: 661
Study 31545636 — intervention group
Group type: COMPARATOR
Intervention: Nondangerous person with depression description
Number of subjects: 661
Study 28792857 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable resistance (WR) equivalent to 12% body mass (BM)
Number of subjects: 16
Study 28792857 — intervention group
Group type: COMPARATOR
Intervention: Traditional (TR) power clean training
Number of subjects: 16
Study 24919820 — intervention group
Group type: EXPERIMENTAL
Intervention: 50mg ipragliflozin
Number of subjects: 168
Study 24919820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 24919820 — intervention group
Group type: EXPERIMENTAL
Intervention: 50mg or 100mg ipragliflozin (during open-label extension)
Number of subjects: 168
Study 23489438 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 2312
Study 20922415 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii (250 mg twice a day for 10 days)
Number of subjects: 48
Study 20922415 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (30 mg/kg twice daily for 10 days)
Number of subjects: 48
Study 20922415 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 48
Study 19773535 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide administered 1 hour after last gemfibrozil dose
Number of subjects: 9
Study 19773535 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide administered 24 hours after last gemfibrozil dose
Number of subjects: 9
Study 19773535 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide administered 48 hours after last gemfibrozil dose
Number of subjects: 9
Study 19773535 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide administered 96 hours after last gemfibrozil dose
Number of subjects: 9
Study 19773535 — intervention group
Group type: COMPARATOR
Intervention: Control phase (repaglinide without prior gemfibrozil)
Number of subjects: 9
Study 19773535 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide metabolism inhibition continued up to 48 hours after gemfibrozil administration
Number of subjects: 9
Study 19773535 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C8 half-life estimation
Number of subjects: 9
Study 16411026 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeling Thermometer with Clinical Marker State (FT+)
Number of subjects: 182
Study 16411026 — intervention group
Group type: COMPARATOR
Intervention: Feeling Thermometer without Clinical Marker State (FT-)
Number of subjects: 182
Study 16411026 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Gamble with Clinical Marker State (SG+)
Number of subjects: 182
Study 16411026 — intervention group
Group type: COMPARATOR
Intervention: Standard Gamble without Clinical Marker State (SG-)
Number of subjects: 182
Study 14659717 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment on normal enamel powder
Number of subjects: 5
Study 14659717 — intervention group
Group type: COMPARATOR
Intervention: Er:YAG laser treatment on NaClO-treated enamel powder
Number of subjects: 5
Study 11471363 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 240
Study 11471363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 9549661 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine bromide 30 mg every 8 hours
Number of subjects: 0
Study 8050422 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibreoptic nasotracheal intubation
Number of subjects: 30
Study 8050422 — intervention group
Group type: COMPARATOR
Intervention: Orthodox nasotracheal intubation
Number of subjects: 30
Study 3184782 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-mg nicotine chewing gum
Number of subjects: 20
Study 3184782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31764076 — intervention group
Group type: EXPERIMENTAL
Intervention: Differentiated service delivery (DSD) eligibility screening
Number of subjects: 3465
Study 31764076 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (ineligibility reasons)
Number of subjects: 3465
Study 31242752 — intervention group
Group type: EXPERIMENTAL
Intervention: Evinacumab (75/150/250 mg subcutaneously or 5/10/20 mg/kg intravenously) in SAD
Number of subjects: 139
Study 31242752 — intervention group
Group type: EXPERIMENTAL
Intervention: Evinacumab (150/300/450 mg subcutaneously once weekly, 300/450 mg every 2 weeks, or 20 mg/kg intravenously once every 4 weeks) in MAD
Number of subjects: 139
Study 31242752 — intervention group
Group type: COMPARATOR
Intervention: Placebo in SAD
Number of subjects: 139
Study 31242752 — intervention group
Group type: COMPARATOR
Intervention: Placebo in MAD
Number of subjects: 139
Study 31242752 — intervention group
Group type: COMPARATOR
Intervention: Placebo in MAD (intravenous)
Number of subjects: 139
Study 28032482 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 15 mg, once daily
Number of subjects: 90
Study 28032482 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal renal function or mild renal impairment)
Number of subjects: 90
Study 24668304 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Choices (4-session motivational interviewing intervention)
Number of subjects: 110
Study 24668304 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study 23537419 — intervention group
Group type: EXPERIMENTAL
Intervention: Study Group (SG) - telemedicine interactions (2 office visits at months 6 and 12, 2 telemedicine interactions at months 3 and 9)
Number of subjects: 100
Study 23537419 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - quarterly office visits
Number of subjects: 100
Study 23537419 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 23537419 — intervention group
Group type: EXPERIMENTAL
Intervention: Study Group (SG)
Number of subjects: 100
Study 22047812 — intervention group
Group type: COMPARATOR
Intervention: Lobeglitazone 0.5 mg (1 subject placebo)
Number of subjects: 61
Study 22047812 — intervention group
Group type: COMPARATOR
Intervention: Lobeglitazone 1, 2, 4, and 8 mg (8 subjects in each group, including 2 receiving placebos)
Number of subjects: 61
Study 22047812 — intervention group
Group type: COMPARATOR
Intervention: Lobeglitazone 1, 2, and 4 mg (once daily for 7 days, 8 subjects in each group, including 2 receiving placebos)
Number of subjects: 61
Study 22047812 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobeglitazone (various doses)
Number of subjects: 61
Study 19672809 — intervention group
Group type: EXPERIMENTAL
Intervention: Online optical coherence pachymetry (OCP)
Number of subjects: 513
Study 19672809 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound pachymetry (USP)
Number of subjects: 513
Study 19672809 — intervention group
Group type: COMPARATOR
Intervention: Comparison of OCP and USP
Number of subjects: 513
Study 16388508 — intervention group
Group type: EXPERIMENTAL
Intervention: First screening round with PSA>or=3.0 ng/ml
Number of subjects: 0
Study 16388508 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat screening round with PSA>or=3.0 ng/ml
Number of subjects: 0
Study 15372387 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-gauge Quincke needle
Number of subjects: 60
Study 15372387 — intervention group
Group type: COMPARATOR
Intervention: 25-gauge Quincke needle
Number of subjects: 60
Study 11737964 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDDM subjects
Number of subjects: 15
Study 11737964 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDDM subjects with complications
Number of subjects: 15